D. Alvaro, M. Bragazzi, A. Benedetti, L. Fabris, G. Fava et al., Cholangiocarcinoma in Italy: A national survey on clinical characteristics, diagnostic modalities and treatment. Results from the ???Cholangiocarcinoma??? committee of the Italian Association for the Study of Liver disease, Digestive and Liver Disease, vol.43, issue.1, pp.60-65, 2011.
DOI : 10.1016/j.dld.2010.05.002

J. West, H. Wood, R. Logan, M. Quinn, and G. Aithal, Trends in the incidence of primary liver and biliary tract cancers in England and Wales, 1971.

B. Glimelius, K. Hoffman, P. Sjoden, G. Jacobsson, H. Sellstrom et al., Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer, Annals of Oncology, vol.7, issue.6, pp.593-600, 1996.
DOI : 10.1093/oxfordjournals.annonc.a010676

S. Rao, D. Cunningham, R. Hawkins, M. Hill, D. Smith et al., Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer, British Journal of Cancer, vol.4, issue.9, pp.1650-1654, 2005.
DOI : 10.1136/gut.48.6.816

G. Kornek, B. Schuell, F. Laengle, T. Gruenberger, M. Penz et al., Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial, Annals of Oncology, vol.15, issue.3, pp.478-483, 2004.
DOI : 10.1093/annonc/mdh096

M. Ducreux, E. Van-cutsem, V. Laethem, J. Gress, T. Jeziorski et al., A randomised phase II trial of weekly high-dose 5-fluorouracil with and without folinic acid and cisplatin in patients with advanced biliary tract carcinoma: results of the 40955 EORTC trial, European Journal of Cancer, vol.41, issue.3, pp.398-403, 2005.
DOI : 10.1016/j.ejca.2004.10.026

N. Androulakis, G. Aravantinos, K. Syrigos, A. Polyzos, N. Ziras et al., Oxaliplatin as First-Line Treatment in Inoperable Biliary Tract Carcinoma, Oncology, vol.70, issue.4, pp.280-284, 2006.
DOI : 10.1159/000096249

F. Eckel and R. Schmid, Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials, British Journal of Cancer, vol.18, issue.6, pp.896-902, 2007.
DOI : 10.1038/sj.bjc.6690452

T. André, R. Vidal, J. Fartoux, L. Ross, P. Leslie et al., Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study, British Journal of Cancer, vol.51, issue.6, pp.862-867, 2008.
DOI : 10.1093/annonc/mdl955

J. Harder, B. Riecken, O. Kummer, C. Lohrmann, F. Otto et al., Outpatient chemotherapy with gemcitabine and oxaliplatin in patients with biliary tract cancer, British Journal of Cancer, vol.22, issue.7, pp.848-852, 2006.
DOI : 10.1038/sj.bjc.6603334

A. Sharma, B. Mohanti, R. V. Shukla, N. Pal, S. Dwary et al., A phase II study of gemcitabine and oxaliplatin (Oxigem) in unresectable gall bladder cancer, Cancer Chemotherapy and Pharmacology, vol.99, issue.6, pp.497-502, 2010.
DOI : 10.1007/s00280-009-1055-0

J. Jang, H. Lim, I. Hwang, H. Song, N. Yoo et al., Gemcitabine and oxaliplatin in patients with unresectable biliary cancer including gall bladder cancer: a Korean Cancer Study Group phase II trial, Cancer Chemotherapy and Pharmacology, vol.16, issue.4, pp.641-647, 2010.
DOI : 10.1007/s00280-009-1069-7

S. Faivre, R. E. Woynarowski, J. Cvitkovic, and E. , Supraadditive effect of 2 ??? ,2 ??? -difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines, Cancer Chemotherapy and Pharmacology, vol.44, issue.2, pp.117-123, 1999.
DOI : 10.1007/s002800050955

A. Sharma, A. Dwary, B. Mohanti, S. Deo, S. Pal et al., Best Supportive Care Compared With Chemotherapy for Unresectable Gall Bladder Cancer: A Randomized Controlled Study, Journal of Clinical Oncology, vol.28, issue.30, pp.4581-4586, 2010.
DOI : 10.1200/JCO.2010.29.3605

P. Zatloukal, L. Petruzelka, M. Zemanová, V. Kolek, J. Skricková et al., Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: a phase III randomized trial, Lung Cancer, vol.41, issue.3, pp.321-331, 2003.
DOI : 10.1016/S0169-5002(03)00233-2

C. Sederholm, G. Hillerdal, K. Lamberg, K. Kölbeck, M. Dufmats et al., Phase III Trial of Gemcitabine Plus Carboplatin Versus Single-Agent Gemcitabine in the Treatment of Locally Advanced or Metastatic Non???Small-Cell Lung Cancer: The Swedish Lung Cancer Study Group, Journal of Clinical Oncology, vol.23, issue.33, pp.8380-8388, 2005.
DOI : 10.1200/JCO.2005.01.2781

D. Santis, M. Bellmunt, J. Mead, G. Kerst, J. Leahy et al., Randomized Phase II/III Trial Assessing Gemcitabine/ Carboplatin and Methotrexate/Carboplatin/Vinblastine in Patients With Advanced Urothelial Cancer ???Unfit??? for Cisplatin-Based Chemotherapy: Phase II???Results of EORTC Study 30986, Journal of Clinical Oncology, vol.27, issue.33, pp.5634-5639, 2009.
DOI : 10.1200/JCO.2008.21.4924

K. Williams, J. Picus, K. Trinkhaus, C. Fournier, R. Suresh et al., Gemcitabine with carboplatin for advanced biliary tract cancers: a phase II single institution study, HPB, vol.12, issue.6, pp.418-426, 2010.
DOI : 10.1111/j.1477-2574.2010.00197.x

D. Malka, P. Cervera, S. Foulon, T. Trarbach, C. De-la-fouchardière et al., Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial, The Lancet Oncology, vol.15, issue.8, pp.819-847, 2014.
DOI : 10.1016/S1470-2045(14)70212-8

J. Mane, E. Iruarrizaga, I. Rubio, E. Fonseca, E. Iza et al., Second-line chemotherapy with capecitabine (CAP) and oxaliplatin (OX) in patients with pancreatic or biliary tree adenocarcinoma (ADC) 2011 Gastrointestinal Cancers Symposium [abstract 308], J Clin Oncol, vol.29, p.4, 2011.

. Fiteni, Advanced biliary tract carcinomas: a retrospective multicenter analysis of first and second-line chemotherapy, BMC Gastroenterology, vol.29, issue.1, p.143, 2014.
DOI : 10.1200/JCO.2010.32.1752

URL : https://hal.archives-ouvertes.fr/inserm-01096384